检索结果-南通市图书馆

FC-DIRECTED ANTIBODY CONJUGATION OF MAGNETIC NANOPARTICLES FOR ENHANCED MOLECULAR TARGETING

Journal of Innovative Optical Health Sciences 2009年第4期2卷 387-396页

作者： ROBABEH REZAEIPOOR renu john STEVEN G.ADIE ERIC J.CHANEY MARINA MARJANOVIC AMY L.OLDENBURG STEPHANIE A.RINNE STEPHEN A.BOPPART Biophotonics Imaging Laboratory Beckman Institute for Advanced Science and Technology University of Illinois at Urbana-Champaign UrbanaILUSA Departments of Electrical and Computer Engineering Bioengineeringand Internal Medicine University of Illinois at Urbana-Champaign UrbanaILUSA

In this study, we report the fabrication of engineered iron oxide magnetic nanoparticles (MNPs)functionalized with anti-human epidermal growth factor receptor type 2 (HER2) antibody totarget the tumor antigen HER2. The Fc-directed conjugation of antibodies to the MNPs aidstheir efficient immunospecific targeting through free Fab portions. The directional specificity ofconjugation was verified on a macrophage cell line. Immunofluorescence studies on macrophagestreated with functionalized MNPs and free anti-HER2 antibody revealed that the antibodymolecules bind to the MNPs predominantly through their Fc portion. Different cell lines with different HER2 expression levels were used to test the specificity of our functionalized nanoprobe formolecular targeting applications. The results of cell line targeting demonstrate that these engineered MNPs are able to differentiate between cell lines with different levels of HER2 expression.

关键词： Nanoprobe molecular imaging cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Non-small cell lung carcinoma(NSCLC):Implications on molecular pathology and advances in early diagnostics and therapeutics

引用

Genes & Diseases 2023年第3期10卷 960-989页

作者： Hafiza Padinharayil Jinsu Varghese Mithun Chacko john Golgodu Krishnamurthy Rajanikant Cornelia M.Wilson Minnatallah Al-Yozbaki Kaviyarasi renu Saikat Dewanjee Rupa Sanyal Abhijit Dey Anirban Goutam Mukherjee Uddesh Ramesh Wanjari Abilash Valsala Gopalakrishnan Alex George Jubilee Centre for Medical Research Jubilee Mission Medical College and Research InstituteThrissurKerala 680005India PG&Research Department of Zoology St.Thomas CollegeKozhencheryPathanamthittaKerala 689641India Department of Medical Oncology Jubilee Mission Medical College and Research InstituteThrissurKerala 680005India School of Biotechnology National Institute of TechnologyCalicutKerala 673601India Canterbury Christ Church University Natural Applied SciencesLife Sciences Industry Liaison LabDiscovery ParkSandwich CT139FFUnited Kingdom Centre of Molecular Medicine and Diagnostics(COMManD) Department of BiochemistrySaveetha Dental College&HospitalsSaveetha Institute of Medical and Technical SciencesSaveetha UniversityChennaiTamil Nadu 600077India Department of Pharmaceutical Technology Jadavpur UniversityKolkataWest Bengal 700032India Department of Botany Bhairab Ganguly CollegeFeeder RoadBelghoriaKolkataWest Bengal 700056India Department of Life Sciences Presidency UniversityKolkataWest Bengal 700073India Department of Biomedical Sciences School of Bio-Sciences and TechnologyVellore Institute of Technology(VIT)VelloreTamil Nadu 632014India

Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention, diagnosis, and management, supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030, surpassing non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC, the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies, followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), tumor educated platelets (TEP), and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer, acquired resistance caused by various generations of therapeutic agents, refractory disease, prognosis, and surveillance.

关键词： Biomarker Clinical trial Epidemiology Histology Liquid biopsy NSCLC Targeted therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：